Iovance Biotherapeutics, Inc. (IOVA)

13,63 +0,75 (+5,82%) Alla chiusura: 04:00PM EDT

Iovance Biotherapeutics, Inc.

825 Industrial Road
Suite 400
San Carlos, CA 94070
United States
650 260 7120
https://www.iovance.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 557

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Frederick G. Vogt Esq., J.D., Ph.D.	Interim CEO, President, General Counsel & Corporate Secretary	1,43M	N/D	1974
Mr. Jean-Marc Bellemin M.B.A.	CFO, Principal Accounting Officer & Treasurer	873,02k	N/D	1972
Dr. Igor P. Bilinsky Ph.D.	Chief Operating Officer	873,02k	N/D	1973
Dr. Friedrich Graf Finckenstein M.D.	Chief Medical Officer	967,97k	N/D	1967
Ms. Sara Pellegrino	Vice President of Investor Relations & Public Relations	N/D	N/D	N/D
Ms. Tracy Winton	Senior Vice President of Human Resources	N/D	N/D	N/D
Mr. Howard B. Johnson M.B.A.	Chief Business Officer	N/D	N/D	1960
Mr. James Ziegler M.B.A.	Executive Vice President of Commercial	N/D	N/D	N/D
Dr. Raj K. Puri M.D., Ph.D.	Executive VP of Regulatory Strategy & Translational Medicine	N/D	N/D	N/D
Mr. Brian Shew M.B.A.	Senior VP & Head of Digital and Information Technology	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Governance aziendale

L'ISS Governance QualityScore di Iovance Biotherapeutics, Inc. al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 6; diritti degli azionisti: 3; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.